Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors
出版年份 2012 全文链接
标题
Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors
作者
关键词
-
出版物
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 109, Issue 45, Pages 18281-18289
出版商
Proceedings of the National Academy of Sciences
发表日期
2012-09-18
DOI
10.1073/pnas.1207759109
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): Five-year (yr) overall survival (OS) data from a phase II trial.
- (2017) R. J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Data processing and analysis with theautoPROCtoolbox
- (2011) Clemens Vonrhein et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
- (2011) Arvin C. Dar et al. Annual Review of Biochemistry
- Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials
- (2011) Chris Coppin et al. BJU INTERNATIONAL
- Improving Drug Candidates by Design: A Focus on Physicochemical Properties As a Means of Improving Compound Disposition and Safety
- (2011) Nicholas A. Meanwell CHEMICAL RESEARCH IN TOXICOLOGY
- Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States
- (2011) Antonia F. Stepan et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
- (2011) B. I. Rini et al. CLINICAL CANCER RESEARCH
- Vascular Endothelial Growth Factor–Targeted Therapies in Advanced Renal Cell Carcinoma
- (2011) Laurence Albiges et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Comprehensive analysis of kinase inhibitor selectivity
- (2011) Mindy I Davis et al. NATURE BIOTECHNOLOGY
- Features and development ofCoot
- (2010) P. Emsley et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Activation State-Dependent Binding of Small Molecule Kinase Inhibitors: Structural Insights from Biochemistry
- (2010) Lisa M. Wodicka et al. CHEMISTRY & BIOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterizing the Effects of the Juxtamembrane Domain on Vascular Endothelial Growth Factor Receptor-2 Enzymatic Activity, Autophosphorylation, and Inhibition by Axitinib
- (2009) James Solowiej et al. BIOCHEMISTRY
- Physicochemical drug properties associated within vivotoxicological outcomes: a review
- (2009) David A Price et al. Expert Opinion on Drug Metabolism & Toxicology
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients
- (2009) K. S. Gajiwala et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting the unactivated conformations of protein kinases for small molecule drug discovery
- (2008) Gordon R Alton et al. Expert Opinion on Drug Discovery
- Naphthamides as Novel and Potent Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: Design, Synthesis, and Evaluation¶
- (2008) Jean-Christophe Harmange et al. JOURNAL OF MEDICINAL CHEMISTRY
- A quantitative analysis of kinase inhibitor selectivity
- (2008) Mazen W Karaman et al. NATURE BIOTECHNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation